"Designing Growth Strategies is in our DNA"

Biopreservation Market Size, Share & Industry Analysis, By Product Type, By Application, By Sample Type, By End User, and Regional Forecast, 2026–2034

Last Updated: November 18, 2026 | Format: PDF | Report ID: FBI119757

 

Biopreservation Market Size and Future Outlook

Play Audio Listen to Audio Version

The biopreservation market size was valued at USD 4.12 billion in 2025. The market is projected to grow from USD 4.48 billion in 2026 to USD 8.46 billion by 2034, exhibiting a CAGR of 8.3% during the forecast period.

Biopreservation refers to the processes and technologies used to maintain viability, stability, and functional characteristics of biological materials during storage, processing, and transportation. It includes preservation media, cryopreservation solutions, freezing and thawing equipment, storage systems, and handling consumables used for cells, tissues, blood, reproductive samples, and other biospecimens. The market growth is being supported by expansion of cell and gene therapies, increasing biobanking activities, growing biomedical research, development of regenerative medicine, and rising demand for reliable long-term storage of sensitive biological materials.

  • For instance, in September 2026, JW Therapeutics announced that China's NMPA (National Medical Products Administration) approved an extension of the cryopreservation period for sorted T cells used as starting material for Carteyva from the previously approved period to 36 months.

Furthermore, Thermo Fisher Scientific Inc., PHC Holdings Corporation, Qingdao Haier Biomedical Co., Ltd., Azenta, Inc., and Danaher are among the prominent companies operating in the global market.

Increasing Adoption of Advanced Cryopreservation Technologies for Cell-Based Therapies is a Prominent Market Trend

Development of advanced cryopreservation technologies is emerging as an important trend in the market. Cell and gene therapies contain sensitive living materials that require controlled preservation during manufacturing, storage, transportation, and administration. In addition, manufacturers are focusing on optimized cryoprotectants, standardized freezing and thawing processes, automated handling, and preservation media designed to maintain post-thaw cell viability and functionality.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rapid Expansion of Cell and Gene Therapy Development to Drive Market Growth

Increasing development and commercialization of cell and gene therapies is a major factor driving the biopreservation market growth. These therapies depend on viable cells and other sensitive biological materials that must retain their functional properties throughout collection, processing, manufacturing, storage, shipment, and clinical administration. In addition, expansion of CAR-T therapies, stem-cell therapies, regenerative medicine, and other advanced therapeutic platforms is consequently increasing demand for specialized preservation media, controlled freezing and thawing technologies, storage systems, and handling consumables.

Market Drivers - Impact & CAGR Contribution (2026–2034)

Rank Market Drivers Overall Impact CAGR Contribution, 2026–2034 Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 Rapid Expansion of Cell & Gene Therapy Development High 2.20% High High High
2 Growing Biobanking and Biospecimen Archiving Activities High 1.75% High High High
3 Increasing Biomedical and Drug Discovery Research Medium 1.50% High High High
4 Rising Adoption of Advanced Cryopreservation Technologies Medium 1.35% Medium High High
5 Growing Demand for Personalized and Regenerative Medicine Medium 1.10% Medium High High
6 Others Low 0.65% Low Medium Medium
Total Positive Growth Contribution 8.55%  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET RESTRAINTS

High Cost of Advanced Cryogenic Storage Infrastructure May Limit Adoption

Advanced biopreservation requires specialized freezers, liquid nitrogen storage systems, temperature monitoring, backup systems, validated consumables, and controlled cold-chain infrastructure. Establishing and maintaining these systems can require substantial capital and operating expenditure. Moreover, smaller laboratories, research institutions, hospitals, and biobanks in cost-sensitive markets may therefore face challenges adopting sophisticated storage technologies. Maintenance, energy requirements, monitoring, qualification, and regulatory compliance further increase total operating costs.

Market Restraints - Impact & Negative CAGR Contribution (2026–2034)

Rank Market Restraints Overall Impact CAGR Contribution, 2026–2034
(2026-2034)
Impact: 2026-2028 Impact: 2029-2031 Impact: 2032-2034
1 High Cost of Advanced Cryogenic Storage Infrastructure High -0.11% High Medium Medium
2 Long replacement cycles and durable product lifespan Medium -0.07% Medium Medium Medium
3 Complex Regulatory and Quality Requirements Medium -0.05% Medium Medium Low
4 Others Low -0.02% Low Low Low
Total Negative Restraint Contribution -0.25%  

Source: Fortune Business Insights

Download Free sample For In-Depth Market Restraints & Risk Analysis

MARKET OPPORTUNITIES

Expansion of Personalized Medicine and Biobanking to Create Significant Growth Opportunities

Growing adoption of precision medicine, genomics, translational research, and longitudinal disease studies is increasing the need for high-quality biological sample collections. Biobanks provide researchers with preserved tissues, blood, cells, DNA-related samples, and other biospecimens required for disease research and biomarker development. Expansion of population biobanks and disease-specific repositories can therefore increase demand for long-term cryogenic storage, sample-tracking technologies, and specialized handling systems.

MARKET CHALLENGES

Maintaining Sample Viability and Standardization Across Cold Chain Remains a Major Challenge

Biological materials can be highly sensitive to temperature fluctuations, freeze-thaw cycles, handling conditions, and storage duration. Improper preservation may reduce cell viability, alter biological characteristics, or compromise sample quality. The challenge becomes particularly important for cell therapies and research samples that may need to be transported between collection centers, manufacturing facilities, biobanks, and clinical sites. Furthermore, developing standardized and validated preservation protocols while maintaining sample integrity across the complete cold chain remains a major industry challenge.

Segmentation Analysis

By Product Type

Growing Need for Large-Scale Biospecimen Storage to Support Storage Systems Segment Growth

Based on product type, the market is segmented into preservation media & solutions, freezing & thawing systems, storage systems, storage & handling consumables, and others.

The storage systems segment held the largest global biopreservation market share in 2025. This is attributed to increasing volumes of biological samples generated by biobanks, research laboratories, pharmaceutical companies, and cell therapy developers. Moreover, ultra-low-temperature freezers and cryogenic storage systems help maintain cells, tissues, blood, and other biospecimens under controlled conditions for extended periods. Expansion of biobanking and biomedical research infrastructure is increasing storage capacity requirements. Furthermore, growing demand for secure long-term sample preservation is supporting segment growth.        

The preservation media & solutions segment is projected to register highest CAGR of 10.2% during the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Application

Growing Collection and Long-Term Storage of Biological Samples to Support Bobanking & Biospecimen Archiving Segment Growth

Based on application, the market is segmented into cell & gene therapy, biobanking & biospecimen archiving, drug discovery & biomedical research, reproductive medicine, and others.

The biobanking & biospecimen archiving segment held the largest market share in 2025. The growth of biobanking & biospecimen archiving segment is attributed to increasing collection and long-term storage of biological samples for clinical research, genomics, precision medicine, and population health studies. Biobanks require controlled preservation environments to maintain sample quality over long periods. Expansion of disease-specific and population-based repositories is increasing demand for storage infrastructure and preservation consumables. Furthermore, increasing utilization of archived biospecimens in drug discovery and biomarker research is supporting segment growth.

The cell & gene therapy segment is projected to register the highest CAGR of 11.1% during the forecast period.

By Sample Type

Increasing Preservation of Blood and Stem Cell Samples to Support Blood, Bone Marrow & Cord Blood Segment Growth

Based on sample type, the market is segmented into cell cultures & cell-based products, blood, bone marrow & cord blood, reproductive samples, tissues & tissue constructs, and others.

The blood, bone marrow & cord blood segment held the largest market share in 2025. This segment growth is attributed to the widespread preservation of hematological samples for transplantation, disease research, diagnostic development, and regenerative medicine. Bone marrow and cord blood contain valuable hematopoietic stem cells that require controlled cryogenic preservation for long-term storage. Expansion of stem-cell banking and hematology research is increasing sample volumes. Furthermore, continued utilization of these samples in clinical and research applications is also supporting segment growth.

The cell cultures & cell-based products segment is projected to register highest CAGR of 10.6% during the forecast period.

By End User

Expanding Cell and Gene Therapy Pipelines Are Expected to Drive Biopharmaceutical & Cell Therapy Companies Segment Growth

Based on end user, the market is segmented into biopharmaceutical & cell therapy companies, biobanks & biorepositories, academic & research institutes, hospitals & clinical laboratories, and others.

The biopharmaceutical & cell therapy companies segment held the largest market share in 2025. Segment growth is attributed to the increasing development and commercialization of cell and gene therapies, which require reliable preservation of cells, tissues, and biological materials throughout manufacturing and distribution. In addition, growing reliance on cryopreservation media and controlled-rate freezing systems to maintain product viability is expected to support adoption across biopharmaceutical manufacturing settings.

The hospital and clinical laboratories segment is projected to register substantial CAGR of 8.0% during the forecast period.

Biopreservation Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa.

North America

North America Biopreservation Market Size, 2025 (USD Billion)

To get more information on the regional analysis of this market, Download Free sample

North America held a dominant share in 2024, valuing at USD 1.52 billion, and also maintained the leading share in 2025, with USD 1.65 billion. The growth of the North American market is attributed to strong biopharmaceutical and biotechnology industries, extensive biomedical research, established biobanking infrastructure, and increasing development of cell and gene therapies.

U.S. Biopreservation Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 1.63 billion in 2026, accounting for roughly 36.3% of global sales.

Europe

Europe is projected to record a considerable growth rate of 7.1% during the forecast period, and reach a valuation of USD 1.16 billion by 2026. The growth of the European market is attributed to established biomedical research infrastructure, biobanking networks, pharmaceutical and biotechnology industries, and increasing cell therapy research.

U.K. Biopreservation Market

The U.K. market in 2026 is estimated at around USD 0.22 billion, representing roughly 5.0% of global revenues.

Germany Biopreservation Market

Germany’s market is projected to reach approximately USD 0.24 billion in 2026, equivalent to around 5.4% of global sales.

Asia Pacific

Asia Pacific is estimated to hold considerable share in the global market and reach USD 1.13 billion in 2026. The growth of the Asia Pacific market is attributed to increasing biomedical research, expansion of cell and gene therapy development, growing biobanking infrastructure, and rising investment in biotechnology.

Japan Biopreservation Market

The Japan market in 2026 is estimated at around USD 0.26 billion, accounting for roughly 5.8% of global revenues.

China Biopreservation Market

China’s market is projected to be one of the largest worldwide, with 2026 revenues estimated at around USD 0.38 billion, representing roughly 8.4% of global sales.

India Biopreservation Market

The India market in 2026 is estimated at around USD 0.13 billion, accounting for roughly 3.0% of global revenues.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The growth of Latin America market is attributed to expanding clinical trial activity and biobank establishment, while government-backed genomics initiatives are driving growth in the Middle East & Africa. The Latin America market is set to reach a valuation of USD 0.23 billion in 2026. In the Middle East & Africa, the GCC is set to reach a value of USD 0.07 billion in 2026.

South Africa Biopreservation Market

The South Africa market is projected to reach around USD 0.04 billion in 2026, representing roughly 1.0% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Product Innovation and Strategic Expansion to Strengthen Key Player’s Market Position

The biopreservation market has a semi-consolidated competitive structure, comprising prominent players such as Thermo Fisher Scientific Inc., PHC Holdings Corporation, Qingdao Haier Biomedical Co., Ltd., Azenta, Inc., and Danaher. These companies are increasingly focusing on integrated solutions for cell and gene therapy workflows as advanced therapies move from clinical development toward commercial manufacturing.

  • For instance, in July 2026, Repligen announced an agreement to acquire BioLife Solutions in a transaction with an enterprise value of approximately USD 1.5 billion.

Other notable players in the global market Eppendorf SE, Merck KGaA, Hamilton Company, Sartorius AG, and Corning Incorporated. These companies are expected to prioritize collaborations to increase their global market share during the forecast period.

LIST OF KEY BIOPRESERVATION COMPANIES PROFILED

  • Thermo Fisher Scientific Inc. (U.S.)
  • PHC Holdings Corporation (Japan)
  • Qingdao Haier Biomedical Co., Ltd. (China)
  • Azenta, Inc. (U.S.)
  • Danaher Corporation (U.S.)
  • Eppendorf SE (Germany)
  • Merck KGaA (Germany)
  • Hamilton Company (U.S.)
  • Sartorius AG (Germany)
  • Corning Incorporated (U.S.)

KEY INDUSTRY DEVELOPMENTS

  • August 2026: San Diego Zoo Wildlife Alliance and Species360 announced a partnership to connect the Frozen Zoo's biobanking information with Species360's global animal-health database, creating an integrated resource for biological sample preservation and conservation research.
  • June 2026: Colossal Biosciences and the U.S. Fish and Wildlife Service announced the BioVault initiative, aimed at collecting, sequencing, and preserving living cells, reproductive tissues, and genomic material from species protected under the U.S. Endangered Species Act.
  • February 2026: CaseBioscience launched CaseCryo CTG DMSO and introduced CaseStor HSS, expanding its portfolio with cell therapy-grade cryopreservation and hypothermic storage solutions for cells and tissues.
  • November 2025: BioLife Solutions opened the Aby J. Mathew Center for Biopreservation Excellence at its expanded Bothell headquarters.
  • March 2025: Teknova and Pluristyx announced the commercial availability of the PluriFreeze cryopreservation system through Teknova.

REPORT COVERAGE

The biopreservation market analysis includes a comprehensive study of the market size & forecast by all the market segments included in the report. It includes details on the market dynamics and market trends expected to drive the market over the forecast period. It provides information on key aspects, including an overview of technological advancements, the regulatory environment, and product launches. Additionally, it details partnerships, mergers & acquisitions, as well as key industry developments and investments by key regions. The global market research report also provides a depth competitive landscape with information on the market share and profiles of key operating players.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year  2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth Rate CAGR of 8.3% from 2026-2034
Unit Value (USD Billion)
Segmentation By Product Type, Application, Sample Type, End User, and Region
By Product Type
  • Preservation Media & Solutions
  • Freezing & Thawing Systems
  • Storage Systems
  • Storage & Handling Consumables
  • Others 
By Application
  • Cell & Gene Therapy
  • Biobanking & Biospecimen Archiving
  • Drug Discovery & Biomedical Research
  • Reproductive Medicine
  • Others  
By Sample Type
  • Cell Cultures & Cell-Based Products
  • Blood, Bone Marrow & Cord Blood
  • Reproductive Samples
  • Tissues & Tissue Constructs
  • Others  
By End User
  • Biopharmaceutical & Cell Therapy Companies
  • Biobanks & Biorepositories
  • Academic & Research Institutes
  • Hospitals & Clinical Laboratories
  • Others  
By Region 
  • North America (By Product Type, Application, Sample Type, End User, and Country)
    • U.S. 
      • By Product Type
    • Canada
      • By Product Type
  • Europe (By Product Type, Application, Sample Type, End User, and Country/Sub-region)
    • Germany 
      • By Product Type
    • U.K.
      • By Product Type
    • France 
      • By Product Type
    • Spain 
      • By Product Type
    • Italy 
      • By Product Type
    • Scandinavia 
      • By Product Type
    • Rest of Europe
      • By Product Type
  • Asia Pacific (By Product Type, Application, Sample Type, End User, and Country/Sub-region)
    • China 
      • By Product Type
    • Japan 
      • By Product Type
    • India 
      • By Product Type
    • Australia 
      • By Product Type
    • Southeast Asia 
      • By Product Type
    • Rest of Asia Pacific 
      • By Product Type
  • Latin America (By Product Type, Application, Sample Type, End User, and Country/Sub-region)
    • Brazil
      • By Product Type
    • Mexico
      • By Product Type
    • Rest of Latin America
      • By Product Type
  • Middle East & Africa (By Product Type, Application, Sample Type, End User, and Country/Sub-region)
    • GCC
      • By Product Type
    • South Africa
      • By Product Type
    • Rest of Middle East & Africa
      • By Product Type

Research Methodology

1. Bottom Up Approaches

Approach 1:  Country-Level Biopreservation Utilization Analysis

  • Estimate country-level volumes of biological samples requiring preservation across cell & gene therapy, biobanking, biomedical research, reproductive medicine, and other applications.
  • Assess utilization of preservation media, freezing and thawing systems, cryogenic storage systems, and handling consumables.
  • Determine biopreservation penetration according to sample type, storage duration, temperature requirements, and end-user category.
  • Calculate market value using: Biological Sample Volume × Biopreservation Product Utilization × Average Selling Price
  • Validate estimates using biobank databases, clinical research activity, cell therapy pipelines, laboratory statistics, and institutional disclosures.
  • Aggregate country-level estimates into regional and global market value.

Approach 2:  Product Volume, Technology Mix & ASP Analysis

  • Estimate annual demand for preservation media & solutions, freezing & thawing systems, storage systems, and storage & handling consumables.
  • Assess utilization across cell cultures, cell-based products, blood, bone marrow, cord blood, reproductive samples, tissues, and tissue constructs.
  • Estimate installed base and replacement demand for ultra-low-temperature freezers, cryogenic storage systems, and related equipment.
  • Validate average selling prices using manufacturer catalogs, distributor pricing, procurement databases, and institutional purchasing information.
  • Cross-check calculated market values against supplier revenues and product-segment disclosures.

Approach 3:  End-User Demand Analysis

  • Identify biopharmaceutical & cell therapy companies, biobanks & biorepositories, academic & research institutes, hospitals, and clinical laboratories.
  • Estimate annual biospecimen volumes and preservation-product consumption by end-user type.
  • Evaluate purchasing patterns across cryopreservation media, freezing and thawing systems, storage equipment, and consumables.
  • Assess installed storage capacity and expansion requirements at major facilities.
  • Aggregate facility-level demand into country and regional estimates.

2. Top Down Approaches

Approach 1:  Manufacturer Revenue & Product Portfolio Analysis

  • Identify major manufacturers operating across biopreservation media, cryogenic storage, freezing and thawing technologies, and sample-handling products.
  • Review annual reports, SEC filings, investor presentations, product catalogs, regulatory filings, and official company disclosures.
  • Estimate revenue attributable specifically to biopreservation products and related technologies.
  • Allocate revenues across product type, application, sample type, end user, and geography.
  • Exclude unrelated laboratory equipment, general diagnostics, non-biological storage products, and other products outside the defined market.
  • Compare manufacturer-derived estimates with bottom-up market calculations.

Approach 2: Triangulation, Validation & Forecast Modeling

  • Compare manufacturer revenues with country-level biopreservation demand.
  • Validate biological sample volumes using biobank databases, biomedical research statistics, clinical trial activity, and cell therapy pipelines.
  • Cross-check technology penetration using clinical adoption, product specifications, and regulatory information.
  • Assess regional growth through biotechnology investment, cell and gene therapy development, biobanking expansion, biomedical research, and healthcare infrastructure.
  • Forecast individual country markets before aggregating regional and global totals.
  • Apply conservative, base-case, and higher-growth forecasting scenarios.
  • Report all market values in USD billion rounded to two decimal places, while maintaining underlying source-data precision for CAGR calculations.

3. List of Key Sources

  • Company annual reports
  • SEC filings
  • Investor presentations
  • Official manufacturer product catalogs
  • Product brochures and technical specifications
  • Instructions for Use
  • U.S. Food and Drug Administration
  • European Medicines Agency
  • ClinicalTrials.gov
  • WHO
  • OECD
  • World Bank
  • National healthcare agencies
  • National biotechnology agencies
  • Biobank directories and registries
  • International Society for Biological and Environmental Repositories (ISBER)
  • National biobanking networks
  • Cell and gene therapy clinical trial databases
  • Pharmaceutical and biotechnology industry databases
  • Academic research institutions
  • Hospital and clinical laboratory databases
  • Stem-cell and cord-blood banking organizations
  • Reproductive medicine associations
  • PubMed
  • Peer-reviewed cryobiology journals
  • Cell and gene therapy journals
  • Government research funding databases
  • Procurement and tender databases
  • Distributor catalogs
  • Official company press releases

4. Primary Interviews

Supply Side Interviews: 60%

  • Key respondents: Biopreservation media manufacturers, cryopreservation solution manufacturers, ultra-low-temperature freezer manufacturers, cryogenic storage system suppliers, freezing and thawing technology providers, storage consumable manufacturers, cell-processing technology companies, distributors, product managers, R&D executives, regulatory professionals, sales directors, and business development managers.

Demand Side Interviews: 40%

  • Key Respondents: Cell and gene therapy developers, biopharmaceutical companies, biobank managers, biorepository professionals, biomedical researchers, laboratory managers, academic research institutions, hospital laboratory professionals, clinical laboratories, reproductive medicine centers, stem-cell banks, cord-blood banks, clinical research organizations, and procurement professionals.


Frequently Asked Questions

According to Fortune Business Insights, the global market value stood at USD 4.12 billion in 2025 and is projected to reach USD 8.46 billion by 2034.

In 2025, the market value stood at USD 1.65 billion.

The market is expected to exhibit a CAGR of 8.3% during the forecast period of 2026-2034.

By product type, the storage systems segment is expected to hold highest share in the market.

Rapid expansion of cell and gene therapy development is drive market growth.

Thermo Fisher Scientific Inc., PHC Holdings Corporation, Qingdao Haier Biomedical Co., Ltd., Azenta, Inc., and Danaher are the major players in the global market.

North America dominated the market in 2025.

Seeking Comprehensive Intelligence on Different Markets?Get in Touch with Our Experts Speak to an Expert
  • 2021-2034
  • 2025
  • 2021-2024
  • 200
Download Free Sample

    man icon
    Mail icon
    Mail icon
Jump to Content

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Healthcare Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann